Impaired Clearance, Not Overproduction of Toxic Proteins, May Underlie Alzheimers's Disease
News Dec 10, 2010
Many believe that accumulation of abnormal levels of beta-amyloid in the brain initiates a cascade of events leading to the death of brain cells and ultimately to dementia. In the rare, early-onset forms of Alzheimer's that are linked to genetic mutations there is a marked increase in beta-amyloid production. In the more common, late-onset form of Alzheimer's, the mechanisms leading to increased beta-amyloid levels are not well understood.
The study, published in Science, was led by senior author Randall Bateman, M.D., an assistant professor of neurology at Washington University in St. Louis. Dr. Bateman and his colleagues previously reported an innovative procedure to measure beta-amyloid levels over time in cerebrospinal fluid (CSF) - the fluid that bathes the brain. In the new study, the researchers used that procedure to measure beta-amyloid production and clearance rates in study volunteers with Alzheimer's disease and in age-matched volunteers free of the disease.
"These findings may help point us toward better diagnostic tests and effective therapies. The next question is what is causing the decreased clearance rate," said Dr. Bateman.
Prior studies in animals suggest several possible explanations for the slower clearance of beta-amyloid in late-onset Alzheimer's. One possibility is that as beta-amyloid accumulates, it acts as a sink for more of the protein, trapping it within the brain. The researchers believe that sorting out these mechanisms is likely to help speed the development of new drugs for the disease.
"Abnormal protein deposits within the brain are a hallmark not only of Alzheimer's disease, but of many neurological disorders. With knowledge about how these proteins accumulate, we may be able to slow that process and reduce the damage to the brain," said Roderick Corriveau, Ph.D., a program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).
Dr. Bateman and his colleagues measured beta-amyloid levels in the CSF of 12 patients with late-onset Alzheimer's and 12 cognitively normal individuals. The participants' average age was 74. Their CSF was sampled every hour for 36 hours, via a one-time lumbar puncture. Throughout the procedure, they were encouraged to stay in bed.
During the first nine hours, the participants received an IV drip containing leucine, a protein building block, which had been labeled with a non-radioactive isotope. By measuring the amount of labeled beta-amyloid by mass spectroscopy over time, the researchers were able to calculate how fast it was produced in the participants' brains and how fast it was cleared. The clearance of beta-amyloid was about 30 percent slower in individuals with Alzheimer's disease than in cognitively normal individuals. This is consistent with previous findings that beta-amyloid is decreased in the CSF of people with Alzheimer's and in those with mild cognitive impairment at high risk of developing the disease.
Dr. Bateman's procedure has enabled researchers to investigate the effects of new drugs aimed at tamping down beta-amyloid levels. The procedure also could be a starting point toward a shorter, simpler test - perhaps a blood test - that measures beta-amyloid clearance rates to detect Alzheimer's prior to the first symptoms.
"This study is significant in that it reports the first measurement of beta-amyloid production and clearance in Alzheimer's," said Marcelle Morrison-Bogorad, Ph.D., director of the Division of Neuroscience at the National Institute on Aging (NIA). "For years scientists believed that it was the overproduction of beta-amyloid that led to its accumulation in the brain. These new findings shift the emphasis to clearance of beta-amyloid. This may lead to development of a diagnostic test as well as identification of new therapeutic targets."
Alzheimer's disease is the most common cause of dementia in older adults, and affects as many as 5.1 million Americans. In the late-onset type of Alzheimer's disease, symptoms usually appear after age 65.
The study was supported in part by NINDS, NIA, the National Center for Research Resources (NCRR), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), all components of NIH. Dr. Bateman is an investigator at the Charles F. and Joanne Knight Alzheimer's Disease Research Center (ADRC) and the Hope Center for Neurological Disorders at Washington University.